Dimerix Bioscience announces research agreement with Takeda Cambridge

Dimerix Bioscience Pty Ltd, a pre-clinical stage product company developing a pipeline of 'best in class' lead products with highly specific activity and with reduced risk of off-target effects, today announced that it has entered into a research agreement with Takeda Cambridge Limited, a UK based subsidiary of Takeda Pharmaceutical Company Limited, Japan's largest pharmaceutical company.

“Dimerix' GPCR-HIT platform enables the development of more specific drugs that take into account the signaling profile of GPCRs acting in heteromeric complexes”

Under the agreement, Dimerix will use its GPCR-HIT platform and leading insights into the ability of G-Protein Coupled Receptors (GPCRs) to form complexes, called heteromers, to work with undisclosed GPCRs of interest to Takeda.

"Dimerix' GPCR-HIT platform enables the development of more specific drugs that take into account the signaling profile of GPCRs acting in heteromeric complexes," said Tim Grogan, CEO of Dimerix. "We are very pleased to be working with Takeda to apply our GPCR-HIT technology. Our interactions with Takeda have been very impressive."

"We are pleased to enter into this agreement to apply Dimerix' GPCR-HIT platform," said Mark Carlton, President of Takeda Cambridge Limited. "This work will continue to build on our knowledge of key GPCRs, which are drug targets of major significance."